Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
ATX
vs
S
S&P/ASX 300
ATX
Over the past 12 months, ATX has underperformed S&P/ASX 300, delivering a return of -23% compared to S&P/ASX 300's +4% growth.
Stocks Performance
ATX vs S&P/ASX 300
Performance Gap
ATX vs S&P/ASX 300
Create a free account · No card needed
Performance By Year
ATX vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Amplia Therapeutics Ltd
Glance View
Amplia Therapeutics is a clinical-stage drug developer focused on medicines that block focal adhesion kinase, or FAK, a protein that helps some cancers and scar-forming diseases grow and spread. Its lead drug candidate is being tested mainly in hard-to-treat cancers, especially pancreatic cancer, and the company also studies related fibrosis indications. It does not sell approved drugs today; its work is centered on research, clinical trials, and building a portfolio of potential treatments. The company’s main customers are not patients directly but future buyers such as pharmaceutical partners, drug distributors, or larger healthcare companies that may license or commercialize its drug candidates if the programs succeed. For now, Amplia makes money mainly through research collaborations, grants, and financing, while it spends to advance its own drug pipeline through trials and regulatory work. If a candidate ever reaches the market, the business could earn licensing income, milestone payments, and eventually product sales or royalties through partners. What makes Amplia different is that it is a focused, single-platform biotech rather than a broad drugmaker. It is betting on one scientific approach—FAK inhibition—to attack diseases where standard treatments often do not work well. That makes the company’s value tied closely to the progress of its specific drug programs and the strength of the underlying science.
Create a free account · No card needed
